<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Volume Spike Investor &#187; ACLI</title>
	<atom:link href="http://vsinvestor.com/tag/acli/feed" rel="self" type="application/rss+xml" />
	<link>http://vsinvestor.com</link>
	<description>Investing in stocks based on short term spikes in volume</description>
	<lastBuildDate>Sat, 05 Nov 2011 14:20:15 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2</generator>
		<item>
		<title>Top Day Trader Alerts (AMGN, ACLI, CTIC, CERS, ERTS, LCAV, NBG, SQNM)</title>
		<link>http://vsinvestor.com/2010/02/top-day-trader-alerts-amgn-acli-ctic-cers-erts-lcav-nbg-sqnm.html</link>
		<comments>http://vsinvestor.com/2010/02/top-day-trader-alerts-amgn-acli-ctic-cers-erts-lcav-nbg-sqnm.html#comments</comments>
		<pubDate>Tue, 09 Feb 2010 13:59:48 +0000</pubDate>
		<dc:creator>247admin</dc:creator>
				<category><![CDATA[pre-market]]></category>
		<category><![CDATA[ACLI]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[CERS]]></category>
		<category><![CDATA[CTIC]]></category>
		<category><![CDATA[ERTS]]></category>
		<category><![CDATA[LCAV]]></category>
		<category><![CDATA[NBG]]></category>
		<category><![CDATA[SQNM]]></category>

		<guid isPermaLink="false">http://vsinvestor.com/?p=3719</guid>
		<description><![CDATA[These are some of the top trading stocks seen on price and volume moves for day traders and active traders: Amgen Inc. (NASDAQ: AMGN) is trading up this morning by 2.25% at $58.75 on almost 200,000 shares on its report that its Phase III head-to-head trial evaluating Denosumab met its primary and secondary endpoints versus [...]]]></description>
			<content:encoded><![CDATA[<p>These are some of the top trading stocks seen on price and volume moves for day traders and active traders:</p>
<p>Amgen Inc. (NASDAQ: AMGN) is trading up this morning by 2.25% at $58.75 on almost 200,000 shares on its report that its Phase III head-to-head trial evaluating Denosumab met its primary and secondary endpoints versus Zometa in a 1900+ study in the treatment of advanced prostate cancer that has progressed to bone metastases.</p>
<p>American Commercial Lines Inc. (NASDAQ: ACLI) is soaring as the top gainer on NASDAQ but on this volume.  The headline earnings were $1.09 EPS vs. $0.06 as revenue fell 16% to $226.9 million versus estimates of $222.5 million.  The revenue drop was blamed on commodities shipped by transportation customers and lower tow revenues as tons/mile volume declined was down 1.4%.  A large short interest exists here at 1.077 million shares or 11.5% of the float.  Shares are up 26% at $20.48 but on 13,000 shares.</p>
<p>Cell Therapeutics, Inc. (NASDAQ: CTIC) is up after a huge sell-off yesterday after the FDA postponed its Oncologic Drugs Advisory Committee Meeting to review Pixantrone due to severe snow conditions around the nation&#8217;s capital. Shares closed at $0.64 and are indicated up around $0.78 on 1.9+ million shares.  Shares were as high as $0.84 in earlier trading.</p>
<p>Cerus Corporation (NASDAQ: CERS) is trading up 16%, even above earlier indications, at $2.35 on 81,000 shares after the company reported positive results of its Phase 1 clinical trial of INTERCEPT red blood cells and on its report that it will collaborate with the French National Transfusion Service on INTERCEPT red blood cell development.</p>
<p>Electronic Arts Inc. (NASDAQ: ERTS) down 7.8% at $16.12 on 700,000 shares; very actively traded to downside last night; this after earnings were mostly in line with estimates but the company lowered guidance all the way out to Fiscal March-2011.</p>
<p>LCA-Vision Inc. (NASDAQ: LCAV) beat earnings this morning but just with a more narrow loss (-$0.19 EPS).  We have not paid attention to the rest of the data from the call but shares are down 9.5% at $5.35 on only about 12,000 shares.  This is rarely a stock that trades in the pre-market.</p>
<p>National Bank of Greece SA (NYSE: NBG) is seeing a major pop up this morning despite a Goldman Sachs downgrade that is way too late.  This is on the major overhaul proposed.  Shares are up 10% at $3.77 on about 40,000 shares.</p>
<p>Sequenom, Inc. (NASDAQ: SQNM) is trading up over 5% at $4.35 this morning on 60,000 shares after the company reported that it licensed the worldwide rights to develop age-related macular degeneration diagnostic test to Optherion and is expected to launch in 2011.</p>
<p>You are invited to <a href="http://247wallst.com/page/free-newsletter/" target="_blank">join our free daily email distribution list</a> to hear about top analyst upgrades and downgrades, IPOs and secondary offerings, ongoing day trader and options trader alerts, stock and market rumors, Buffett and guru investor news, M&amp;A and more.</p>
<p>Price snapshots as of 8:40 to 8:50 AM EST</p>
<p>JON C. OGG<br />
FEBRUARY 9, 2010</p>
]]></content:encoded>
			<wfw:commentRss>http://vsinvestor.com/2010/02/top-day-trader-alerts-amgn-acli-ctic-cers-erts-lcav-nbg-sqnm.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

